Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Warning Beteiligungs GmbH is a private German investment firm headquartered in Wiesbaden, specializing in the life sciences and biotechnology sectors. The company is primarily recognized for its role as a long-term strategic investor in c-LEcta GmbH, a prominent industrial biotechnology firm focused on enzyme engineering for the pharmaceutical and food industries. Warning Beteiligungs has participated in several of c-LEcta's financing rounds alongside other notable investors like High-Tech Gründerfonds (HTGF) and SHS Gesellschaft für Beteiligungsmanagement. The firm is led by Klaus Warning, an experienced professional in the chemical and biotech industries. Following the acquisition of a majority stake in c-LEcta by Givaudan in 2022, Warning Beteiligungs remains an active entity in the German investment landscape.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Warning Beteiligungs.